StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.52−0.08 (-5.00%)

Close on Nov 18, 2026Market cap $12.53MP/E –Yield –

Lipocine operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lipocine's operating income for the twelve months ending Jun 30, 2026 was -$12.57M. For fiscal 2025 it was -$10.37M. The highest annual figure on record is $3.88M in fiscal 2012.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.37M–
FY2024Dec 31, 2024-$1.16M–
FY2023Dec 31, 2023-$17.93M–
FY2022Dec 31, 2022-$12.12M-485.3%
FY2021Dec 31, 2021$3.15M–
FY2020Dec 31, 2020-$18.00M–
FY2019Dec 31, 2019-$12.90M–
FY2018Dec 31, 2018-$11.33M–
FY2017Dec 31, 2017-$21.22M–
FY2016Dec 31, 2016-$19.19M–
FY2015Dec 31, 2015-$18.38M–
FY2014Dec 31, 2014-$20.48M–
FY2013Dec 31, 2013-$10.68M-375.5%
FY2012Dec 31, 2012$3.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$2.84M–
Q1 FY2026Mar 31, 2026-$3.85M–
Q4 FY2025Dec 31, 2025-$2.52M-262.8%
Q3 FY2025Sep 30, 2025-$3.36M–
Q2 FY2025Jun 30, 2025-$2.40M–
Q1 FY2025Mar 31, 2025-$2.09M-164.9%
Q4 FY2024Dec 31, 2024$1.55M–
Q3 FY2024Sep 30, 2024-$2.63M–
Q2 FY2024Jun 30, 2024-$3.29M–
Q1 FY2024Mar 31, 2024$3.22M–
Q4 FY2023Dec 31, 2023-$2.59M–
Q3 FY2023Sep 30, 2023-$7.04M–
Q2 FY2023Jun 30, 2023-$3.96M–
Q1 FY2023Mar 31, 2023-$4.34M–
Q4 FY2022Dec 31, 2022-$2.56M-120.0%
Q3 FY2022Sep 30, 2022-$2.90M–
Q2 FY2022Jun 30, 2022-$3.53M–
Q1 FY2022Mar 31, 2022-$3.13M–
Q4 FY2021Dec 31, 2021$12.78M–
Q3 FY2021Sep 30, 2021-$3.53M–
Q2 FY2021Jun 30, 2021-$2.99M–
Q1 FY2021Mar 31, 2021-$3.11M–
Q4 FY2020Dec 31, 2020-$4.80M–
Q3 FY2020Sep 30, 2020-$4.38M–
Q2 FY2020Jun 30, 2020-$4.22M–
Q1 FY2020Mar 31, 2020-$4.60M–
Q4 FY2019Dec 31, 2019-$3.45M–
Q3 FY2019Sep 30, 2019-$2.98M–
Q2 FY2019Jun 30, 2019-$3.35M–
Q1 FY2019Mar 31, 2019-$3.13M–
Q4 FY2018Dec 31, 2018-$3.17M–
Q3 FY2018Sep 30, 2018-$2.35M–
Q2 FY2018Jun 30, 2018-$3.16M–
Q1 FY2018Mar 31, 2018-$2.64M–
Q4 FY2017Dec 31, 2017-$5.40M–
Q3 FY2017Sep 30, 2017-$4.77M–
Q2 FY2017Jun 30, 2017-$6.14M–
Q1 FY2017Mar 31, 2017-$4.91M–
Q4 FY2016Dec 31, 2016-$3.02M–
Q3 FY2016Sep 30, 2016-$3.29M–

More Lipocine figures

See a number that looks wrong?